Is the association of serum sodium with mortality in patients with type 2 diabetes explained by copeptin or NT-proBNP? (ZODIAC-46)

Atherosclerosis

Volumn 242, Issue 1, 2015, Pages 179-185

  Riphagen, Ineke J ^a,b   Logtenberg, Susan J J ^a,c   Groenier, Klaas H ^a,c   van Hateren, Kornelis J J ^c   Landman, Gijs W D ^c,d   Struck, Joachim ^e   Navis, Gerjan ^a   Kootstra Ros, Jenny E ^a   Kema, Ido P ^a   Bilo, Henk J G ^a,c   Kleefstra, Nanne ^a,c,f   Bakker, Stephan J L ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e THERMO FISHER SCIENTIFIC   (Germany)

^f LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

Author keywords

All cause mortality; Cardiovascular mortality; Serum sodium; Type 2 diabetes

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; COPEPTIN; SODIUM; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; GLYCOPEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SODIUM BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOPEPTIDES; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SODIUM;

EID: 84937239449     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.07.010     Document Type: Article

References (35)

1. Spasovski G., Vanholder R., Allolio B., Annane D., Ball S., Bichet D., et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol. Dial. Transpl. 2014, 29(Suppl. 2):i1-i39.
2. Corona G., Giuliani C., Parenti G., Norello D., Verbalis J.G., Forti G., et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One 2013, 8(12):e80451.
3. Liamis G., Rodenburg E.M., Hofman A., Zietse R., Stricker B.H., Hoorn E.J. Electrolyte disorders in community subjects: prevalence and risk factors. Am. J. Med. 2013, 126(3):256-263.
4. Mohan S., Gu S., Parikh A., Radhakrishnan J. Prevalence of hyponatremia and association with mortality: results from NHANES. Am. J. Med. 2013, 126(12). 1127,37.e1.
5. Sajadieh A., Binici Z., Mouridsen M.R., Nielsen O.W., Hansen J.F., Haugaard S.B. Mild hyponatremia carries a poor prognosis in community subjects. Am. J. Med. 2009, 122(7):679-686.
6. Kovesdy C.P., Lott E.H., Lu J.L., Malakauskas S.M., Ma J.Z., Molnar M.Z., et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation 2012, 125(5):677-684.
7. Milo-Cotter O., Cotter G., Weatherley B.D., Adams K.F., Kaluski E., Uriel N., et al. Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. Eur. J. Heart Fail. 2008, 10(2):196-200.
8. Gankam-Kengne F., Ayers C., Khera A., de Lemos J., Maalouf N.M. Mild hyponatremia is associated with an increased risk of death in an ambulatory setting. Kidney Int. 2013, 83(4):700-706.
9. Schrier R.W., Sharma S., Shchekochikhin D. Hyponatraemia: more than just a marker of disease severity?. Nat. Rev. Nephrol. 2013, 9(1):37-50.
10. Zerbe R.L., Vinicor F., Robertson G.L. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 1979, 28(5):503-508.
11. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch. Intern Med. 2001, 161(7):996-1002.
12. Kannel W.B., Ho K., Thom T. Changing epidemiological features of cardiac failure. Br. Heart J. 1994, 72(2 Suppl. l):S3-S9.
13. Riphagen I.J., Boertien W.E., Alkhalaf A., Kleefstra N., Gansevoort R.T., Groenier K.H., et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care 2013, 36(10):3201-3207.
14. Fenske W., Wanner C., Allolio B., Drechsler C., Blouin K., Lilienthal J., et al. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J. Am. Soc. Nephrol. 2011, 22(4):782-790.
15. Miller W.L., Grill D.E., Struck J., Jaffe A.S. Association of hyponatremia and elevated copeptin with death and need for transplantation in ambulatory patients with chronic heart failure. Am. J. Cardiol. 2013, 111(6):880-885.
16. Ubink-Veltmaat L.J., Bilo H.J., Groenier K.H., Rischen R.O., Meyboom-de Jong B. Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth. J. Med. 2005, 63(3):103-110.
17. Drion I., Kleefstra N., Landman G.W., Alkhalaf A., Struck J., Groenier K.H., et al. Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29). Diabetes Care 2012, 35(11):2354-2358.
18. Lutgers H.L., Gerrits E.G., Sluiter W.J., Ubink-Veltmaat L.J., Landman G.W., Links T.P., et al. Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10). PLoS One 2009, 4(8):e6817.
19. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann. Intern Med. 2009, 150(9):604-612.
20. Levey A.S., Coresh J., Greene T., Marsh J., Stevens L.A., Kusek J.W., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin. Chem. 2007, 53(4):766-772.
21. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 2006, 52(1):112-119.
22. de Goeij M.C., van Diepen M., Jager K.J., Tripepi G., Zoccali C., Dekker F.W. Multiple imputation: dealing with missing data. Nephrol. Dial. Transpl. 2013, 28(10):2415-2420.
23. Sterne J.A., White I.R., Carlin J.B., Spratt M., Royston P., Kenward M.G., et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009, 338:b2393.
24. Harel O., Zhou X.H. Multiple imputation: review of theory, implementation and software. Stat. Med. 2007, 26(16):3057-3077.
25. Fenske W., Stork S., Blechschmidt A., Maier S.G., Morgenthaler N.G., Allolio B. Copeptin in the differential diagnosis of hyponatremia. J. Clin. Endocrinol. Metab. 2009, 94(1):123-129.
26. Schrier R.W. Body water homeostasis: clinical disorders of urinary dilution and concentration. J. Am. Soc. Nephrol. 2006, 17(7):1820-1832.
27. Iwasaki Y., Kondo K., Murase T., Hasegawa H., Oiso Y. Osmoregulation of plasma vasopressin in diabetes mellitus with sustained hyperglycemia. J. Neuroendocrinol. 1996, 8(10):755-760.
28. Richards A.M., Crozier I.G., Yandle T.G., Espiner E.A., Ikram H., Nicholls M.G. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br. Heart J. 1993, 69(5):414-417.
29. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000, 355(9210):1126-1130.
30. Slagman M.C., Waanders F., Vogt L., Damman K., Hemmelder M., Navis G., et al. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrol. Dial. Transpl. 2012, 27(3):983-990.
31. Boertien W.E., Riphagen I.J., Drion I., Alkhalaf A., Bakker S.J., Groenier K.H., et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 2013, 56(8):1680-1688.
32. Velho G., Bouby N., Hadjadj S., Matallah N., Mohammedi K., Fumeron F., et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013, 36(11):3639-3645.
33. Bankir L., Bouby N., Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease?. Nat. Rev. Nephrol. 2013, 9(4):223-239.
34. KDOQI KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007, 49(2 Suppl. 2):S12-S154.
35. Hernan M.A., Hernandez-Diaz S., Werler M.M., Mitchell A.A. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am. J. Epidemiol. 2002, 155(2):176-184.